Updated results of the PRIMA study confirms the benefit of 2-years rituximab maintenance in follicular lymphoma patients responding to immunochemotheraphy
Autor: | Salles, GA, Catalano, J, Feugier, P, Offner, FC, Bouabdallah, R, Caballero, D, Brice, P, Pedersen, Lars Møller, Haioun, C, Belada, D, Delmer, A, Simpson, D, Tilly, H, Leppa, S, Soubeyran, P, Hagenbeek, A, Casasnovas, O, Intragumtornchai, T, Fermé, C, Gomes de Silva, M, Sebban, C, Lister, A, Esrell, JA, Milone, G, Sonet, A, Lopez-Guillermo, A, Seymour, JF |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2010 |
Zdroj: | Salles, GA, Catalano, J, Feugier, P, Offner, FC, Bouabdallah, R, Caballero, D, Brice, P, Pedersen, L M, Haioun, C, Belada, D, Delmer, A, Simpson, D, Tilly, H, Leppa, S, Soubeyran, P, Hagenbeek, A, Casasnovas, O, Intragumtornchai, T, Fermé, C, Gomes de Silva, M, Sebban, C, Lister, A, Esrell, JA, Milone, G, Sonet, A, Lopez-Guillermo, A & Seymour, JF 2010, ' Updated results of the PRIMA study confirms the benefit of 2-years rituximab maintenance in follicular lymphoma patients responding to immunochemotheraphy ', Blood, vol. 116, pp. 746 . |
Databáze: | OpenAIRE |
Externí odkaz: |